Policy | April 01, 2024
Venus Remedies receives Rs. 2.50 crore under PLI scheme
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
The approval has been accorded by IFCI Limited for manufacturing of the product "7 ACA"
The minister exhorted the pharmaceutical sector to prepare a plan for the next 25 years
The company inaugurated the new production line at the Bengaluru facility to manufacture Computed Tomography Scanners
It is one of the 15 medical device manufacturers approved under the government’s PLI scheme
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)